Business Wire

CD-CAPITAL

30.11.2022 11:05:38 CET | Business Wire | Press release

Share
CD Capital’s Carmel Daniele Successfully Nominated in 2022’s Edition of “100 Global Inspirational Women in Mining” (WIM100)

CD Capital is thrilled to announce Carmel Daniele’s successful nomination in 2022’s edition of “100 Global Inspirational Women in Mining” (WIM100), a biennial publication that celebrates the “above & beyond” contributions of women to the mining industry, across all roles, seniority and jurisdictions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221129005553/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Carmel Daniele nominated in 2022's WIM100 (Photo: Business Wire)

CD Capital is proud that Ms Daniele has received this recognition for her pioneering work within the mining private equity sector. Ms Daniele, CD Capital’s Founder and Chief Investment Officer commented,

“I feel both honoured and humbled to have been nominated for this prestigious award to stand alongside many other pioneering women in our field. By working together, we make a powerful force in creating positive change for the future and inspiring other women to join our sector that is key to the greening of our planet for generations to come”.

Ms Daniele is a leader in her field, having established CD Capital in 2006, being one of the first in London to set up a dedicated fund focused on private mining assets and winning a prestigious mining finance industry award in 2008. She has since launched two further natural resource funds and has raised c.$1bn in capital from leading institutional investors. CD Capital’s global portfolio invests in the development of projects that will supply critical minerals for the green transition, as well as the key ingredients used in fertilisers to ensure food security for the world. Projects are primarily in jurisdictions that can rely on their own abundance of green energy, such as Latin America, Canada, Australia and Europe.

Since establishing CD Capital, Ms Daniele has built a world-class investment technical team of industry insiders. Ms Daniele also actively sponsors women studying Geology at Imperial College through its internship and mentoring programme.

The 100 Global Inspirational Women in Mining 2022 publication includes more on WIM100 on page 3 and features Ms Daniele on page 47. In 2022, WIM 100 received 915 nominations for 491 women in mining from 61 countries.

These 100 inspirational women have been chosen using the following selection criteria:

1. She is a trailblazer: A WIM100 woman is a pioneer. She is an innovator. She makes positive and impactful changes so the industry can operate in a more sustainable, inclusive and safer way.

2. She advocates and empowers: A WIM100 woman offers proactive advocacy to those working in the mining industry and beyond. She empowers her colleagues to ensure everyone feels heard, welcomed and respected.

3. She perseveres in the face of adversity: A WIM100 woman is resilient and determined. She has the courage to speak up, challenge the status quo and break barriers.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221129005553/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 15:00:00 CEST | Press release

New Washington State facility provides capacity to manufacture more than 30,000 radars annually, strengthening the U.S. defense industrial base As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructu

Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 15:00:00 CEST | Press release

Analysis of more than 1,200 production cloud environments provides a first-hand view into how organizations are embedding AI into business-critical workflows, exposing new security risks that traditional controls weren't built to address. Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become ope

Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 15:00:00 CEST | Press release

Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai's health system network Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's co

SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release

The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9.7.2026 14:45:00 CEST | Press release

Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.bus

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye